Winton Group’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-42
Closed -$41K – 1266
2021
Q3
$41K Sell
42
-27
-39% -$17.5K ﹤0.01% 1308
2021
Q2
$40K Sell
69
-49
-42% -$31.6K ﹤0.01% 1403
2021
Q1
$93K Sell
118
-10
-8% -$10.1K 0.01% 1338
2020
Q4
$130K Sell
128
-189
-60% -$131K 0.01% 1241
2020
Q3
$182K Buy
317
+183
+137% +$109K 0.01% 1358
2020
Q2
$78K Sell
134
-10
-7% -$5.75K ﹤0.01% 1407
2020
Q1
$65K Sell
144
-76
-35% -$68.8K ﹤0.01% 1350
2019
Q4
$375K Sell
220
-12
-5% -$10.4K 0.01% 1320
2019
Q3
$110K Buy
+232
New +$126K ﹤0.01% 1455

Other funds holding MTNB

Winton Group's MTNB Position: Q4 2021 in Review

Winton Group sold out of Matinas BioPharma (MTNB) in Q4 2021, closing a stake of 42 shares — an estimated $41K sold.

Winton Group first reported a position in MTNB in Q3 2019 and held it in 9 quarters. The position peaked at $375K in Q4 2019. 64 funds tracked by Wall St. Rank hold MTNB as of Q4 2021.

  • Winton Group reported no remaining Matinas BioPharma position as of Q4 2021 after selling out during the quarter.
  • Winton Group sold 42 Matinas BioPharma shares in Q4 2021, an estimated $41K.
  • Winton Group first reported a position in Matinas BioPharma in Q3 2019 and held it in 9 quarters.
  • Winton Group's Matinas BioPharma position peaked at $375K in Q4 2019.
  • 64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.